Key result
Inhibition of Src kinase caused a weak reversal in GPVI-mediated platelet aggregation, whereas inhibition of Syk or Btk did not.
Why the study?
Src tyrosine kinases and Syk contribute to sustained platelet aggregation under arterial shear, but whether they are required for aggregation under minimal shear following GPVI or CLEC-2 activation was unknown.
Src kinase, but not Syk or Btk, plays a role in sustaining GPVI-mediated platelet aggregation under minimal shear conditions.
Answers are grounded in this paper and cite their sources.
Src inhibition modestly reverses aggregation in this model; hypothesis-generating for pathway-specific antithrombotics, requiring human validation.
Src tyrosine kinases and spleen tyrosine kinase (Syk) have recently been shown to contribute to sustained platelet aggregation on collagen under arterial shear. In the present study, we have investigated whether Src and Syk are required for aggregation under minimal shear following activation of glycoprotein VI (GPVI) and have extended this to C-type lectin-like receptor-2 (CLEC-2) which signals through the same pathway. Aggregation was induced by the GPVI ligand collagen-related peptide (CRP) and the CLEC-2 ligand rhodocytin and monitored by light transmission aggregometry (LTA). Aggregation and tyrosine phosphorylation by both receptors were sustained for up to 50 min. The addition of inhibitors of Src, Syk or Bruton's tyrosine kinase (Btk) at 150 sec, by which time aggregation was maximal, induced rapid loss of tyrosine phosphorylation of their downstream proteins, but only Src kinase inhibition caused a weak (~10%) reversal in light transmission. A similar effect was observed when the inhibitors were combined with apyrase and indomethacin or glycoprotein IIb-IIIa (GPIIb-IIIa) antagonist, eptifibatide. On the other hand, activation of GPIIb-IIIa by GPVI in a diluted platelet suspension, as measured by binding of fluorescein isothiocyanate-labeled antibody specific for the activated GPIIb-IIIa (FITC-PAC1), was reversed on the addition of Src and Syk inhibitors showing that integrin activation is rapidly reversible in the absence of outside-in signals. The results demonstrate that Src but not Syk and Btk contribute to sustained aggregation as monitored by LTA, possibly as a result of inhibition of outside-in signaling from GPIIb-IIIa to the cytoskeleton through a Syk-independent pathway. This is in contrast to the role of Syk in supporting sustained aggregation on collagen under arterial shear.
No takes yet. Share an insight, caveat, or question.
Cheung et al. (2022) studied Platelet aggregation. Src, Syk, and Btk inhibitors was evaluated on Reversal of platelet aggregation measured by light transmission aggregometry. Inhibition of Src kinase caused a weak reversal in GPVI-mediated platelet aggregation, whereas inhibition of Syk or Btk did not.
Synapse has enriched 10 related papers. Consider them for comparative context: